Denali Therapeutics Inc. (DNLI)

Over the past six months, Denali Therapeutics' stock price has been influenced by several events. As of February 6, 2026, the closing stock price was $21.08, with a 52-week high of $23.77 and a low of $10.57. The FDA extended the review period for Denali's Hunter Syndrome drug on October 13, 2025. On February 5, 2026, an analyst call highlighted positive preliminary data for DNL126, indicating significant biomarker reductions and a favorable safety profile, supporting potential accelerated approval in 2027. Analyst ratings have been generally positive, with a consensus 'Buy' rating from multiple firms, including BTIG and UBS. Short interest in Denali Therapeutics increased by 2.05% as of January 15, 2026, with 11.58% of the public float sold short.

There is no indication of traditional demand seasonality for Denali Therapeutics' products or services. Demand for its therapies is typically driven by disease prevalence, clinical trial outcomes, regulatory approvals, and market access, rather than seasonal fluctuations.

Denali Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for neurodegenerative and lysosomal storage diseases, operating within the Healthcare sector and Biotechnology industry. The company's pipeline targets conditions like Alzheimer's, Parkinson's, ALS, and MPS IIIA, utilizing proprietary technologies such as the ATLAS and ETV platforms to cross the blood-brain barrier. Key product candidates include Tividenofusp alfa for MPS II, DNL126 for MPS IIIA, DNL593 for FTD-GRN, BIIB122/DNL151 for Parkinson's, DNL343 for ALS and FTD, DNL788 for ALS and Parkinson's, and Buntanetap for Alzheimer's, along with other programs targeting LRRK2, RIPK1, TREM2, and Tau.

Denali Therapeutics is headquartered in South San Francisco, California, and was founded in 2013. The company primarily operates in the United States, with research sites in Cambridge, Massachusetts. Denali also engages in global partnerships to extend its research impact and support worldwide clinical trials.

Denali Therapeutics generally holds a positive brand reputation within the investment community, reflected by a consensus 'Buy' rating from analysts, with an average rating score of around 1.11 to 1.5 on a scale of 1 to 5. There were no specific events in the past year explicitly detailed in the search results that negatively impacted Denali Therapeutics' brand reputation.

Denali Therapeutics has a diverse ownership structure, with institutional investors holding a significant portion of the stock, ranging from approximately 40.24% to 97.16%. Insiders own about 6.75%, while public companies and individual investors hold approximately 2.84% to 53.01% of the stock. Major institutional owners include Vanguard Group Inc., Baillie Gifford & Co., BlackRock, Inc., Fmr Llc, T. Rowe Price Investment Management, Inc., UBS Asset Management Americas Inc, State Street Corp, Temasek Holdings, Capital Research Global Investors and Biogen Inc.